Bronco FCU Selects Tyfone to Enrich Retail and Business Digital Banking Experiences
Bronco FCU selects Tyfone to enrich retail and business digital banking experiences
Share
'When assessing our options on the market, we had a clear goal: enhance self-service to better serve our members and position the credit union for future growth,' said Steve Pittman, CIO of Bronco FCU. 'We selected Tyfone not only because of its forward-thinking platform architecture and commitment to innovation but they also have a deep understanding of the credit union industry.'
Headquartered in Franklin, Va., Bronco FCU has more than 18,000 members and manages $273 million in assets. nFinia offers flexibility, robust security and API-driven integration capabilities, making it an ideal choice to support the credit union's long-term digital roadmap to ensure members can manage their finances with ease while knowing that their digital banking tools are available when they need them. Additionally, Bronco FCU will adopt Tyfone's automated loan processing solutions, Quick Pay and Skip-a-Pay, to enable members to streamline the process of completing or skipping loan payments without requiring log-in credentials.
'Their team didn't just demonstrate features, they actually walked us through how nFinia would solve members' unique needs,' explained Pittman. 'It was clear early on that this team shared our vision and approach. We appreciated their insight, positive energy, and the easy rapport that developed from day one. Their cooperative structure and shared values also align perfectly with our culture at Bronco, which made the decision even easier.'
'We are thrilled to welcome Bronco FCU to the Tyfone family,' said Siva Narendra, CEO of Tyfone. 'Its commitment to innovation and exceptional service aligns perfectly with our mission to empower financial institutions with secure, user-friendly digital banking solutions. With Bronco FCU's team, we're focused on delivering the best digital experience for its members, helping to grow the credit union's membership.'
About Bronco Federal Credit Union
Bronco Federal Credit Union is a not-for-profit, member-owned credit union proudly serving over 18,000 members throughout Franklin, Suffolk, and surrounding communities in southeastern Virginia. Since 1941, Bronco has delivered personalized, trustworthy financial services—from everyday banking to home and business lending—while maintaining a deep commitment to community engagement and member relationships. With a focus on innovation and service, Bronco FCU is dedicated to meeting members where they are – through digital convenience, in-branch support, and education – so they can achieve their financial goals at every stage of life. Welcome home. Welcome to Bronco. To learn more visit www.broncofcu.com.
About Tyfone Inc.
Based in Portland, Ore., Tyfone is a leading provider of consumer and commercial digital banking services for community financial institutions throughout the U. S. We understand that an elegant, engaging, intuitive user experience is the minimum requirement for any digital banking provider. What differentiates Tyfone is our unwavering commitment to continuous innovation, exceptional collaboration, and superior execution. We consider each customer a true partner and place the highest value on every relationship. To learn more about Tyfone, visit Tyfone.com and connect on LinkedIn.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Quanterix Accelerator Laboratory Awarded Rigorous New York State Clinical Laboratory Permit
Permit approval enables expanded research capabilities and underscores commitment to accuracy, reliability, and scientific excellence BILLERICA, Mass., August 21, 2025--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced the New York State Department of Health (NYSDOH) has granted the Quanterix Accelerator Laboratory a clinical laboratory permit in the Clinical Chemistry category. The permit approval expands advanced biomarker research led by Quanterix, deepening collaborations with clinical, pharmaceutical, and research partners. The Quanterix Accelerator Lab is now fully CLIA-certified in all 50 states, enabling comprehensive clinical testing and biomarker analysis nationwide. "Collaboration is at the core of the Quanterix Accelerator Laboratory," said Masoud Toloue, PhD, Chief Executive Officer of Quanterix. "Every breakthrough therapy and clinical trial begins with strong partnerships. Securing this permit reaffirms our commitment to quality and compliance and enables us to extend our expertise to a broader network of clinical and research partners." The Quanterix Accelerator Laboratory is a cutting-edge facility leveraging ultra-sensitive Simoa® technology to deliver unmatched precision in protein biomarker detection, supporting biopharmaceutical research, clinical testing, and custom assay development. Certified under the Clinical Laboratory Improvement Amendments (CLIA) program, the Lab has developed 100+ custom assays and supported over 264 global clinical trials across neurology, immunology/oncology, and infectious diseases, combining rapid turnaround with dedicated project management to accelerate discovery and therapeutic innovation. The latest achievement in a series of growth milestones for the Lab, the new permit underscores Quanterix's commitment to meeting the highest benchmarks for accuracy, reliability, and safety. As one of the nation's largest healthcare markets, New York's clinical testing standards are among the most comprehensive in the country, requiring labs to meet rigorous Clinical Laboratory Evaluation Program (CLEP) standards. Accelerator's Simoa® NfL Laboratory Developed Test (LDT) gained approval as part of the laboratory permitting. Authorizations for additional clinical tests are planned to further broaden the available test menu. Additionally, operating under the Quanterix Accelerator Laboratory, the Lucent Diagnostics brand now provides advanced serum and plasma biomarker testing to the clinical and research community. This integration combines the Accelerator Lab's rigor and ultra-sensitive Simoa® technology with Lucent Diagnostics' focus on delivering actionable clinical insights, expanding the reach and impact of biomarker-driven discovery and diagnostics. To learn more about the Quanterix Accelerator Laboratory, visit: About QuanterixQuanterix is a global leader in ultra-sensitive biomarker detection, enabling breakthroughs in disease research, diagnostics, and drug development. Its proprietary Simoa® technology delivers industry-leading sensitivity, allowing researchers to detect and quantify biomarkers in blood and other fluids at concentrations far below traditional limits. With more than 3,600 peer-reviewed publications, Quanterix has been a trusted partner to the scientific community for nearly two decades. In 2025, Quanterix acquired Akoya Biosciences, The Spatial Biology Company®, adding multiplexed tissue imaging with single-cell resolution to its portfolio and 1,396 installed instruments. Together, the combined company offers a uniquely integrated platform that connects biology across blood and tissue—advancing precision medicine from discovery to diagnostics. Learn more at View source version on Contacts Media Contact Marissa Klaassenmedia@ Sign in to access your portfolio
Yahoo
2 hours ago
- Yahoo
Meritage Homes Announces Quarterly Cash Dividend and $500M Increase to Share Repurchase Authorization
SCOTTSDALE, Ariz., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Meritage Homes Corporation (NYSE: MTH, 'Meritage' or the 'Company'), the fifth-largest homebuilder in the U.S., today announced that its Board of Directors has declared a quarterly dividend of $0.43 per share. This dividend is payable on September 30, 2025 to shareholders of record as of the close of trading on September 16, 2025. Meritage's Board of Directors has also approved a $500 million increase to the Company's share repurchase authorization. About Meritage Homes Corporation Meritage is the fifth-largest public homebuilder in the United States, based on homes closed in 2024. The Company offers energy-efficient and affordable entry-level and first move-up homes. Operations span across Arizona, California, Colorado, Utah, Tennessee, Texas, Alabama, Florida, Georgia, Mississippi, North Carolina, and South Carolina. Meritage has delivered over 200,000 homes in its 40-year history, and has a reputation for its distinctive style, quality construction, and award-winning customer experience. The Company is an industry leader in energy-efficient homebuilding, an eleven-time recipient of the U.S. Environmental Protection Agency's (EPA) ENERGY STAR® Partner of the Year for Sustained Excellence Award and Residential New Construction Market Leader Award, as well as a four-time recipient of the EPA's Indoor airPLUS Leader Award. For more information, visit Contacts: Emily Tadano, VP Investor Relations and External Communications (480) 515-8979 (office) investors@
Business Wire
3 hours ago
- Business Wire
Quanterix Accelerator Laboratory Awarded Rigorous New York State Clinical Laboratory Permit
BILLERICA, Mass.--(BUSINESS WIRE)-- Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced the New York State Department of Health (NYSDOH) has granted the Quanterix Accelerator Laboratory a clinical laboratory permit in the Clinical Chemistry category. The permit approval expands advanced biomarker research led by Quanterix, deepening collaborations with clinical, pharmaceutical, and research partners. The Quanterix Accelerator Lab is now fully CLIA-certified in all 50 states, enabling comprehensive clinical testing and biomarker analysis nationwide. "Every breakthrough therapy and clinical trial begins with strong partnerships. Securing this permit reaffirms our commitment to quality and compliance and enables us to extend our expertise to a broader network of clinical and research partners.' Share 'Collaboration is at the core of the Quanterix Accelerator Laboratory,' said Masoud Toloue, PhD, Chief Executive Officer of Quanterix. 'Every breakthrough therapy and clinical trial begins with strong partnerships. Securing this permit reaffirms our commitment to quality and compliance and enables us to extend our expertise to a broader network of clinical and research partners.' The Quanterix Accelerator Laboratory is a cutting-edge facility leveraging ultra-sensitive Simoa ® technology to deliver unmatched precision in protein biomarker detection, supporting biopharmaceutical research, clinical testing, and custom assay development. Certified under the Clinical Laboratory Improvement Amendments (CLIA) program, the Lab has developed 100+ custom assays and supported over 264 global clinical trials across neurology, immunology/oncology, and infectious diseases, combining rapid turnaround with dedicated project management to accelerate discovery and therapeutic innovation. The latest achievement in a series of growth milestones for the Lab, the new permit underscores Quanterix's commitment to meeting the highest benchmarks for accuracy, reliability, and safety. As one of the nation's largest healthcare markets, New York's clinical testing standards are among the most comprehensive in the country, requiring labs to meet rigorous Clinical Laboratory Evaluation Program (CLEP) standards. Accelerator's Simoa ® NfL Laboratory Developed Test (LDT) gained approval as part of the laboratory permitting. Authorizations for additional clinical tests are planned to further broaden the available test menu. Additionally, operating under the Quanterix Accelerator Laboratory, the Lucent Diagnostics brand now provides advanced serum and plasma biomarker testing to the clinical and research community. This integration combines the Accelerator Lab's rigor and ultra-sensitive Simoa ® technology with Lucent Diagnostics' focus on delivering actionable clinical insights, expanding the reach and impact of biomarker-driven discovery and diagnostics. To learn more about the Quanterix Accelerator Laboratory, visit: About Quanterix Quanterix is a global leader in ultra-sensitive biomarker detection, enabling breakthroughs in disease research, diagnostics, and drug development. Its proprietary Simoa ® technology delivers industry-leading sensitivity, allowing researchers to detect and quantify biomarkers in blood and other fluids at concentrations far below traditional limits. With more than 3,600 peer-reviewed publications, Quanterix has been a trusted partner to the scientific community for nearly two decades. In 2025, Quanterix acquired Akoya Biosciences, The Spatial Biology Company ®, adding multiplexed tissue imaging with single-cell resolution to its portfolio and 1,396 installed instruments. Together, the combined company offers a uniquely integrated platform that connects biology across blood and tissue—advancing precision medicine from discovery to diagnostics. Learn more at
